1. Background
Behavioral symptoms result from many neurologic conditions, including cerebrovascular disease, frontotemporal dementia (FTD), and stroke, and determine the patient's future performance (1). The evidence shows that behavioral symptoms are prevalent in neurologic diseases and negatively affect patients' function, and in many cases, they are the patient's chief complaint (2). In dementia, considering different stages of the disease, neuropsychiatric symptoms such as depression, psychosis, restlessness, aggression, apathy, sleep disorders, and disinhibition are seen in more than 90% of cases (2). In some cases, neuropsychiatric representations become apparent even before dementia and increase the burden on the caregiver (3). They also cause several behavioral and interpersonal problems for the patient, along with the underlying disease (4). Regardless of cognitive problems, neuropsychiatric symptoms such as depression, apathy, irritability, mood lability, and sleep and eating problems are associated with impaired daily function in various types of dementia.
Alzheimer's disease (AD) is associated with agitation, irritability, and mood lability. Likewise, vascular dementia is seen in association with apathy (5). Idiopathic Parkinson's disease (PD) is also one of the most common neurodegenerative disorders known as motor disease, while a significant part of the disease burden is related to neuropsychiatric symptoms. The most common psychiatric symptom in PD is depression, which has a clinical prevalence of about 35%. Another important symptom is apathy, which leads to decreased activity. Approximately one-third of Parkinson's patients suffer from anxiety disorders. Although different aspects of cognition are affected in this disease, neuropsychiatric manifestations also significantly impact the patient's performance and usually appear before other disease symptoms (6). Several sleep problems are associated with AD, including fragmentation of nocturnal sleep, insomnia, diurnal drowsiness, and circadian rhythm sleep disorder (7). Psychiatric problems such as depression, anxiety, and irritability are common in patients with Huntington's disease (HD); in most cases, they precede movement symptoms (8) .In many cases, the association of brain pathology with cognitive problems has been established. Attention and memory problems could be considered the symptoms of subcortical pathology. Regarding the findings of imaging studies, brain atrophy is the most stable finding for cognitive decline in patients with multiple sclerosis (MS) (9, 10).
Likewise, some studies have shown a significant relationship between brain pathology and neuropsychiatric symptoms. MRI revealed an association between right frontal lobe atrophy and anxiety score in MS. Depressive disorders are more common in MS with lesions in the left arcuate fasciculus, prefrontal cortex, anterior temporal lobe, and parietal lobe (9).
Some behavioral symptoms may have predictive values for neurological disorders and cognitive dysfunction; for example, impulse control disorders, which constitute a wide range of presentations, are very common in PD and are associated with executive dysfunction and impaired visuospatial capacity (11). Moreover, the presence of REM sleep behavioral disorder in PD predicts mild cognitive impairment (12). In PD, apathy is associated with executive dysfunction. Moreover, apathy is related to the evaluated level of cortical amyloidopathy. Regardless of diagnosis, lesions in frontostriatal pathways, orbitofrontal cortex, ventral pallidum, and ventral tegmental area are underlying joint mechanisms of cognitive decline and apathy syndrome (13). The lesions of the prefrontal subcortical limbic regions are among the first complications of Alzheimer's disease. Depression, anxiety, irritability, aggression, apathy, vegetative symptoms, motor restlessness, hallucinations, and delusions all reflect this (3). Elderly depression is considered a prodrome of dementia and has a significant role in developing persistent cognitive disabilities. The above-mentioned problem has been linked to an increased risk of dementia, including PD and AD.
Evidence shows depressive symptoms may result in the progression of mild cognitive impairment to dementia (14). So far, several studies have investigated the relationship between behavioral symptoms and cognitive problems. In most of these studies, the aim was to assess the overall cognitive function, while the patient's performance in different cognitive domains has not been comprehensively studied. In previous studies, a limited range of behavioral symptoms has been considered simultaneously. Although there is a complex two-way association between cognitive changes and neuropsychiatric symptoms, behavioral symptoms are often considered a consequence of cognitive disorders, and their role as a precedent to cognitive disorders is ignored. In addition, some studies have sought to link behavioral symptoms to lesions in specific areas of the brain.
2. Objectives
In the present study, we aimed to indicate whether neuropsychiatric symptoms could predict concomitant cognitive impairments in patients with neurological disorders.
3. Methods
3.1. Study Design and Conduct
We performed a retrospective review of the medical records of 220 patients with neuropsychiatric disorders. This descriptive-analytical study was conducted at Ayatollah Kashani hospital in Isfahan, Iran.
3.2. Patient Population
Data used in the preparation of this article were obtained from the Ayatollah Kashani hospital database. Patients with cognitive complaints admitted to the neuropsychiatry unit of Ayatollah Kashani hospital from September 1, 2018, to August 31, 2020, were included in the study. A total of 220 hospitalized patients were included in the screening.
By evaluating patients' medical records, a neuropsychiatrist screened all 220 patient records. Patients with malingering diagnoses and those unable to perform neuropsychological tests were excluded from the study. Based on the inclusion and exclusion criteria, all eligible patient records were included, indicating that 211 patient records were finally recruited for this study.
3.3. Baseline Characteristics
First, the background data on age, education, gender, and handedness were collected according to medical records. Education was calculated as the maximum level achieved.
3.4. Behavioral Assessment
Detailed information about the patient's subjective experiences and objective behavior was collected from medical records based on the history, semi-structured clinical interviews, and discharge reports. History was obtained and documented through semi-structured interviews by the neuropsychiatry fellow and the attending neuropsychiatrist; clinical neuropsychiatric evaluation was performed and documented by the same fellow and attending neuropsychiatrist.
The following clinical symptoms were determined and recorded: Apathy, disinhibition, irritability, agitation, aggression, delusion, visual hallucination, auditory hallucination, other hallucinations, anxiety, depressed mood, talkativity, movement symptoms, and sleep-wake cycle disturbances.
3.5. Neuropsychological Assessments
The neuropsychiatry unit cognitive (NUCog) assessment tool was used to assess the cognitive function of all 211 patients. It consists of five subscales to assess cognitive domains: Attention, visuospatial, memory, executive function, and language. The maximum score for each domain is 20, and the maximum total score is 100 (15) .The NUCog tool is valid and reliable for the diagnosis of dementia. It is a quick bedside tool used by various specialists. The NUCog can identify patients with dementia at early stages when other tests, such as MMSE, are not sensitive enough to make the distinction. At a cut-off score of 80/100, the sensitivity of NUCog for distinguishing patients with dementia was 0.84, with a specificity of 0.86 (16). The Persian version of NUCog reliably differentiates the healthy group from patients with mild neurocognitive disorders (at 86.5/100 with a sensitivity of 83.3% and specificity of 87.5%) and patients with Alzheimer's dementia from a healthy group (at 75/100 with a sensitivity and specificity of 100%) (15).
3.6. Statically Analysis
Statistical analyses were performed in SPSS version 20. A comparison of cognitive scores between the two groups was made using a t-test concerning the presence of each behavioral/motor symptom.
The sample size was small, so we used the Shapiro-Wilk test to assess the normality of cognitive variables. The P-value for each cognitive domain was less than 0.05, so we concluded that the cognitive variables were not normally distributed. Therefore, we had to use a non-parametric version of the test, which does not assume normality. With this in mind, the Gamma distribution was used.
We used a generalized linear model to identify whether neuropsychiatric symptoms are associated with an increased risk of cognitive decline, both in general and sub-groups of cognitive domains. A P-value of less than 0.05 was taken as significant.
4. Results
We enrolled 211 patients in the study. Descriptive statistics were used to describe the study population's demographic data, behavioral symptoms, and cognitive function.
Table 1 demonstrates the demographic characteristics. We found that 34.6% (n = 73) of the patients had 12 years of education, 21.5% (n = 45) had five years of education, and 12.8% (n = 27) had eight years of education. Moreover, 9% (n =19) of them were illiterate. Table 2 shows behavioral/motor symptoms. The prevalence of at least one motor/behavioral symptom in the participants was 100%.
Variables | No. (%) |
---|---|
Amotivation | 63 (29.9) |
Apathy | 41 (19.4) |
Disinhibition | 95 (45) |
Irritability | 64 (30.3) |
Aggression | 45 (21.3) |
Agitation | 20 (9.5) |
Auditory hallucination | 6 (2.8) |
Visual hallucination | 14 (6.6) |
Other hallucinations | 1 (0.5) |
Delusion | 37 (17.5) |
Sleep disturbance | 69 (32.7) |
Anxiety | 80 (37.9) |
Depression | 38 (18) |
Talkativeness | 20 (9.5) |
Movement abnormality | 69 (32.7) |
Behavioral/Motor Variables of the Study Population
All details in the cognitive domains are shown in Table 3.
Variables | N | Minimum-Maximum | Mean ± SD |
---|---|---|---|
Attention | 211 | 0 - 20 | 9.960 ± 4.8897 |
Visuoconstruction | 211 | 5 - 20 | 13.794 ± 3.7371 |
Memory | 211 | 0 - 20 | 10.682 ± 4.4648 |
Executive function | 211 | 0 - 20 | 10.908 ± 5.0934 |
Language | 211 | 2 - 20 | 16.618 ± 3.2470 |
NUCog total | 211 | 10 - 99 | 61.931 ± 19.1583 |
Cognitive Parameters of the Study Population (NUCog Mean Score and Subscores)
We also used the Shapiro-Wilk test to assess the normality of cognitive variables, showing that the distribution of cognitive variables departed significantly from normality.
The results of regression coefficients (mean difference) of NUCog subscales for clinical symptoms of patients using a generalized linear model (GLM) with gamma distribution and link function log are demonstrated in Table 4.
Variables | NUCog | |
---|---|---|
Mean Difference (95%CI) | P-Value | |
Gender/male (female ref.) | -0.003 (-0.086 - 0.079) | 0.935 |
Age/year | -0.002 (-0.005 - 0.000) | 0.064 |
Education/year | 0.035 (0.026 - 0.044) | < 0.001 |
Handedness/right (left ref.) | 0.006 (-0.179 - 0.190) | 0.952 |
Amotivation/no (yes ref.) | 0.017 (-0.069 - 0.103) | 0.695 |
Apathy/no (yes ref.) | 0.131 (0.019 - 0.243) | 0.021 |
Disinhibition/no (yes ref.) | 0.023 (-0.064 - 0.111) | 0.500 |
Irritability/no (yes ref.) | -0.008 (-0.106 - 0.090) | 0.874 |
Aggression/no (yes ref.) | 0.038 (-0.066 - 0.143) | 0.469 |
Agitation/no (yes ref.) | 0.182 (0.050 - 0.314) | 0.007 |
Hallucination/no (yes ref.) | -0.103 (-0.667 - 0.461) | 0.721 |
Visual hallucination/no (yes ref.) | 0.059 (-0.106 - 0.225) | 0.481 |
Delusion/no (yes ref.) | 0.082 (-0.030 - 0.194) | 0.150 |
Sleep disorder/no (yes ref.) | 0.084 (-0.169 - 0.001) | 0.052 |
Anxiety/no (yes ref.) | 0.043 (-0.134 - 0.047) | 0.348 |
Depressed mood/no (yes ref.) | 0.011 (-0.119 - 0.097) | 0.839 |
Talkativeness/no (yes ref.) | -0.030 (-0.171 - 0.111) | 0.677 |
Movement/no (yes ref.) | -0.001 (-0.083 - 0.081) | 0.984 |
Regression Coefficients (Mean Difference) of NUCog Total Score for Clinical Symptoms of Patients Using Generalized Linear Model (GLM) with Gamma Distribution and Link Function Log (n = 211)
The correlations of total cognitive scores with behavioral/motor symptoms are demonstrated in Table 5. The cognitive scores were included as the dependent variables. Behavioral/motor symptoms were predictors of cognitive ability. All results were obtained after controlling for age, gender, education, and handedness.
Variables | Attention | Visuoconstruction | Memory | Executive Function | Language | |||||
---|---|---|---|---|---|---|---|---|---|---|
Mean Difference (95%CI) | P-Value | Mean Difference (95%CI) | P-Value | Mean Difference (95%CI) | P-Value | Mean Difference (95%CI) | P-Value | Mean Difference (95%CI) | P-Value | |
Gender/male (female ref.) | 0.03 (-0.09 - 0.16) | 0.625 | 0.04 (-0.03 - 0.11) | 0.189 | 0.02 (-0.09 - 0.13) | 0.738 | -0.06 (-0.19 - 0.08) | 0.402 | -0.03 (-0.09 - 0.04) | 0.413 |
Age/year | -0.001 (-0.005 - 0.003) | 0.431 | -0.002 (-0.004 - 0.001) | 0.157 | -0.004 (-0.08 - -0.001) | 0.023 | -0.005 (-0.01 - 0.0) | 0.036 | -0.001 (-0.003 - 0.001) | 0.245 |
Education/year | 0.06 (0.01-0.05) | < 0.001 | 0.031 (0.024 - 0.039) | < 0.001 | -0.04 (0.03 (0.05) | < 0.001 | 0.04 (0.03 - 0.05) | < 0.001 | 0.02 (0.01 - 0.03) | < 0.001 |
Handedness/right (left ref.) | 0.07 (-0.37 - 0.21) | 0.517 | -0.03 (-0.19 - 0.12) | 0.708 | -0.03 (-0.28 - 0.22) | 0.830 | 0.22 (-0.09 - 0.53) | 0.164 | 0.02 (-0.12 - 0.16) | 0.774 |
Amotivation/no (yes ref.) | -0.01 (-0.15 - 0.12) | 0.853 | 0.01 (-0.06 - 0.08) | 0.769 | 0.07 (-0.04 - 0.19) | 0.202 | 0.03 (-0.12 - 0.17) | 0.706 | -0.02 (-0.08 - 0.05) | 0.557 |
Apathy/no (yes ref.) | 0.16 (-0.02 - 0.34) | 0.081 | 0.04 (-0.05 - 0.14) | 0.378 | 0.24 (0.09 - 0.39) | 0.002 | 0.13 (-0.06 - 0.32) | 0.168 | 0.05 (-0.03 - 0.14) | 0.214 |
Disinhibition/no (yes ref.) | 0.07 (-0.07 - 0.21) | 0.279 | 0.005 (-0.07 - 0.08) | 0.885 | 0.07 (-0.05 - 0.19) | 0.247 | 0.01 (-0.13 - 0.16) | 0.856 | -0.002 (-0.07 - 0.06) | 0.962 |
Irritability/no (yes ref.) | -0.04 (-0.20 - 0.11) | 0.519 | 0.001 (-0.08 - 0.08) | 0.974 | 0.04 (-0.09 - 0.17) | 0.601 | 0.001 (-0.16 - 0.16) | 0.988 | -0.03 (-0.10 - 0.05) | 0.477 |
Aggression/no (yes ref.) | 0.09 (-0.07 - 0.26) | 0.183 | 0.03 (-0.06 - 0.11) | 0.589 | -0.02 (-0.16 - 0.13) | 0.825 | 0.05 (-0.22 - 0.13) | 0.605 | 0.05 (-0.03 - 0.13) | 0.200 |
Agitation/no (yes ref.) | 0.25 (0.03 - 0.45) | 0.049 | 0.15 (0.04 - 0.26) | 0.015 | 0.22 (0.04 - 0.40) | 0.018 | 0.32 (0.09 - 0.54) | 0.005 | 0.05 (-0.05 - 0.14) | 0.366 |
Hallucination/no (yes ref.) | 0.69 (-0.19 - 10.5) | 0.123 | 0.12 (-0.39 - 0.57) | 0.120 | -0.49 (-10.2 - 0.26) | 0.200 | -0.72 (-0.17 - 0.22) | 0.134 | 0.17 (-0.25 - 0.59) | 0.430 |
Visual hallucination/no (yes ref.) | 0.23 (-0.04 - 0.48) | 0.057 | 0.01 (-0.13 - 0.15) | 0.831 | 0.13 (-0.09 - 0.35) | 0.247 | 0.02 (-0.29 - 0.26) | 0.901 | -0.01 (-0.13 - 0.12) | 0.952 |
Delusion/no (yes ref.) | 0.05 (-0.12 - 0.22) | 0.536 | 0.08 (-0.02 - 0.18) | 0.128 | 0.21 (0.06 - 0.36) | 0.006 | 0.21 (0.03 - 0.40) | 0.026 | -0.02 (-0.09 - 0.07) | 0.733 |
Sleep disorder/no (yes ref.) | -0.11 (-0.25 - 0.02) | 0.080 | -0.01 (-0.23 - 0.19) | 0.916 | -0.11 (-0.23 - 0.003) | 0.056 | -0.13 (-0.27 - 0.02) | 0.086 | -0.04 (-0.10 - 0.02) | 0.227 |
Anxiety/no (yes ref.) | -0.15 (-0.29 - -0.01) | 0.024 | -0.01 (-0.09 - 0.06) | 0.698 | -0.03 (-0.15 - 0.09) | 0.692 | -0.06 (-0.21 - 0.09) | 0.421 | -0.04 (-0.11 - 0.03) | 0.261 |
Depressed mood/no (yes ref.) | -0.01 (-0.16 - 0.18) | 0.853 | -0.03 (-0.13 - 0.06) | 0.321 | -0.04 (-0.11 - 0.18) | 0.637 | -0.03 (-0.21 - 0.15) | 0.765 | -0.02 (-0.10 - 0.06) | 0.623 |
Talkativeness/no (yes ref.) | -0.05 (-0.27 - 0.17) | 0.641 | 0.00 (-0.12 - 0.12) | 0.994 | -0.06 (-0.25 - 0.13) | 0.549 | -0.04 (-0.27 - 0.19) | 0.761 | -0.01 (-0.12 - 0.09) | 0.796 |
Movement disorder/no (yes ref.) | 0.04 (-0.09 - 0.17) | 0.495 | 0.002 (-0.07 - 0.07) | 0.948 | 0.004 (-0.11 - 0.12) | 0.940 | 0.006 (0.13 - 0.14) | 0.927 | -0.01 (-0.07 - 0.05) | 0.827 |
Regression Coefficient (Mean Difference) of NUCog Subscales for Clinical Symptoms of Patients Using Generalized Linear Model (GLM) with Gamma Distribution and Link Function Log (n = 211)
5. Discussion
This cross-sectional study investigated the ability of neuropsychiatric symptoms to predict concomitant cognitive impairments in patients with neurological disorders. Considering clinical symptoms, there was a statistically significant negative association between sleep disturbance, agitation, and apathy and the total score of the NUCog.
In addition, the score of the NUCog's memory subscale was correlated negatively with sleep symptoms, apathy, agitation, and delusion. We also found that visual hallucination had a significant negative association with the score of the attention subscale. Delusion and agitation were also associated with lower scores of executive function. In addition, agitation had a negative correlation with the language subscale score.
The neuropsychiatric symptoms of dementia were previously considered a complication of severe dementia and labeled as "behavioral and psychological symptoms of dementia." However, neuropsychiatric symptoms are inevitable in dementia, which may appear at any stage of the disease. One study reported that apathy is a harbinger of cognitive decline in the early stages of HD (17). This finding is consistent with our study, suggesting that behavioral symptoms are not exclusive for late-stage dementia. Although the prevalence and severity of behavioral problems increase with the increasing severity of cognitive disease, sometimes even in cases of mild cognitive impairment, depression and apathy are among the most common problems of the patient (18). In patients with language variant FTD, the inability to convey their mental concepts may lead to agitation even in the early stage. Amotivation in patients with the behavioral type of FTD may result from working memory deficits. These findings confirm the traditional belief that cognitive decline precedes behavioral symptoms (19). Apathy is associated with high levels of dysfunction in daily activities and is one of the symptoms of frontal lobe dysfunction in patients with AD and PD, so it acts as a prelude to cognitive impairment (20). Negative symptoms such as decreased emotional experience, poverty of speech, isolation, and abulia are associated with executive function deficits. Aggression, including self-injurious behavior, as a positive symptom, is also associated with executive dysfunction (21). This shows that cognitive decline does not always occur first; sometimes, both occur together. On the other hand, behavioral symptoms accompanying cognitive problems could be considered a coping strategy for patients' adaptation to reduced mental ability. For example, patients with AD may use persecutory delusion as a compensatory mechanism to explain the reason for lost objects (due to gaps of memory that lead to misplacement) (22).
One study revealed a strong relationship between prospective memory loss and apathy, with control of global cognitive functioning, working memory, and processing speed (23). The evolving apathy may also be an adaptive mechanism administered to redistribute limited cognitive resources to overwhelming environmental stimuli; meanwhile, agitation emerges when this compensatory mechanism is not used (24). Neuroimaging investigations also revealed the co-occurrence of behavioral symptoms and neuroanatomical changes in patients with neurological disorders. Psychotic features have been repeatedly reported with increased beta-amyloid plaques in the cerebral cortex, especially in the pre-subiculum area, decreased neurons in the CA1 hippocampus and parahippocampal gyrus, and high levels of neurofibrillary tangles in the middle frontal cortex. Neuroimaging in Alzheimer's disease also demonstrated an association between apathy and hypometabolism in the anterior cingulate gyrus and orbitofrontal areas. The increased load of neurofibrillary tangles in the orbitofrontal cortex and decreased number of neurons in the locus coeruleus were associated with agitation and aggression, respectively (25). It can be said that the relationship between behavioral symptoms and specific locations in the brain has a proven role in the cognitive process. The relationship between cognitive decline and behavioral symptoms is beyond the cause-and-effect relationship; they may predict each other, which is in line with our findings. Moreover, the connection between apathy and dementia has been shown in AD. Apathy and frontal dysfunction, especially anterior cingulate cortex (ACC) abnormalities, are seen at the same time (26).
The relationship between sleep disorders and Alzheimer's disease is multidimensional, and the interaction between sleep and Aβ plays an important role. Sleep disorders increase Aβ production and decrease Aβ removal. On the other hand, when Aβ accumulates, sleep disturbances increase (27). In the present study, a negative correlation between sleep disorders and performance in memory tasks was reported. This is in line with previous studies that reported sleep, memory, and CSF AD biomarkers were closely interrelated with dementia progression since the disease's asymptomatic and preclinical early stages (28). Persistent short sleep duration at ages 50, 60, and 70 compared to persistent normal sleep duration was also associated with a 30% increased dementia risk independently of sociodemographic, behavioral, cardiometabolic, and mental health factors (29). Therefore, AD as a proteinopathy and sleep disturbance as a homeostatic-refreshing process would predict one another. Confirming this principle, in the present study, the generalized linear model enabled us to predict cognitive ability in the presence of sleep problems.
In mild cognitive impairment, amyloid deposition is related to decreased sleep quality and satisfaction, although there is no reduction in the quantity of sleep (30). Nevertheless, even a mere decrease in sleep quality increases Aβ accumulation in the precuneus (31). On the other hand, decreased quantity of nocturnal sleep leads to elevated Aβ levels in the right hippocampus and thalamus in healthy older adults (32).
Tau pathology, another underlying mechanism in Alzheimer's disease, is associated with sleep disorders. Abnormal tau accumulation in the brainstem, thalamus, hypothalamus, midbrain, and basal forebrain, which are related to sleep regulation, occurs even before cortical amyloid proteinopathy or cortical tauopathy (33). Moreover, it has been shown that the level of interstitial fluid tau depends on the sleep-wake cycle, and CSF tau is correlated with sleep deprivation (34). Therefore, tau pathology has a pivotal role in sleep disturbance in AD (35). Even before the onset of cortical symptoms, sleep problems can be an early indicator of tauopathy, and since tauopathy is the most critical proteinopathy in Alzheimer's disease, sleep disturbances can be a predictor of cognitive problems, especially memory dysfunction. The power of this prediction increases when PET scans also show tauopathy in non-cortical regions. The level of orexin, known for its crucial role in sleep-wake cycle regulation, arousal, and appetite, is increased in advanced Alzheimer's disease, which is closely related to tau protein levels (36). Since one of the most important features of AD is memory dysfunction, the increase in the orexin level in CSF is also evidence of the association between sleep regulation and cognitive performance, especially in the memory domain.
Asymmetric atrophy, especially in the right temporal and left frontal lobes, right hippocampus, and right parietal cortex, was reported in patients with delusional features in primary psychiatric disorders (37, 38). On the other hand, delusions in AD were associated with high levels of pre-subiculum neurofibrillary tangles, increased plaques, and decreased neuronal counts in the CA1 area of the hippocampus (39). Considering the cognitive function of these areas, the association of delusion with memory and executive dysfunction seems logical. In fact, our result in this study is in line with previous studies.
Pro-inflammatory cytokines induce the main symptoms of major mental disorders such as delusions of schizophrenia. Increased serum concentrations of IL-2, IL-6, and IL-8 have been reported in schizophrenia or elevated IL-1β levels in the CSF of schizophrenic patients (40). Limbic structures like the hippocampus have an essential role in memory and also contain more enzymes involved in an inflammatory response than other areas of the brain; these areas may incur the risk of damage from inflammation (41). The association of inflammatory factors with both delusions and memory problems can confirm the findings of our study.
There was lower metabolic activity in the left inferior parietal lobule in patients with multiple delusions than in those with only one type of delusion; hence parietal hypometabolism is associated with more advanced cognitive deficits in AD. It can be said that more delusions predict more cognitive deficits in AD (42). Therefore, memory impairment, the most important cognitive problem in AD, can be associated with delusions.
The presence of hallucinations, especially visual and auditory, has been shown to increase cognitive decline (43). The relationship between cognitive impairment and visual hallucinations in PD is bidirectional. Visual hallucinations may precede cognitive decline or, in the presence of dementia, lead to faster decline. Even hallucinations in patients with PD who do not have cognitive problems are associated with executive impairments, and poorer sustained attention, and visuospatial dysfunction (44). One of the most critical problems of AD is aggression, which is especially troublesome for their caregivers and leads to a poor functional state in patients. Common concepts are often used for agitation and aggression, including wandering, restlessness, and other disorganized behavior. Since the prefrontal cortex, hippocampus, and ACC play an essential role in the aggression-related circuit, the components of this circuit are probably crucial in agitation (45). Therefore, similar to our findings, various cognitive deficits related to these areas of the brain can be expected in patients with agitation.
Agitation in patients with dementia is associated with structural and functional deficits in the hippocampus, posterior cingulate gyrus, anterior cingulate gyrus, insula, amygdala, and frontal areas. Volume loss in these areas results in agitation (46). SPECT studies confirmed the association between agitation and hypo-perfusion in the left anterior temporal, right parietal, and bilateral dorsal frontal cortex (47). Other functional neuroimaging studies show that agitation is associated with cingulate hypometabolism (48). Clinico-pathological studies indicate that the interactions of the dorsolateral prefrontal cortex, orbitofrontal cortex, and ACC with the sensory cortex, amygdala, and medial temporal regions have the leading role in mood regulation. Lesions in these regions lead to aggression and agitation (49). These findings may explain the association between cognitive decline and agitation.
The presence of agitation is associated with lower scores on executive performance. Neuropathologically, agitation is associated with neurofibrillary tangles deposition in the orbitofrontal cortex and ACC. In addition, patients with Alzheimer's type dementia are more likely to be agitated in the presence of frontal and temporal lobe hypometabolism (50). Given the role of ACC in attention and the role of the temporal lobe in memory, it seems to be a persuasive argument for the association between agitation and cognitive domains such as attention and memory.
Therefore, our study showed that the symptoms of apathy, agitation, delusion, visual hallucinations and sleep disturbances significantly increase the likelihood of cognitive deficits in patients with neurological disorders.
5.1. Limitations and Strengths
The present study had several strengths. Unlike previous studies that assessed the relationship of a limited number of behavioral symptoms with only one or two cognitive domains, we evaluated the association of a wide range of behavioral symptoms with five cognitive domains. Previous studies have been performed on specific diseases such as AD and MS, while we examined the relationship between these variables regardless of clinical diagnosis. We used GLM, and therefore, our results can be used to predict cognitive disturbances. The main limitation of our study is cross-sectional analysis. Future studies should conduct longitudinal research to discover the cause-and-effect relationship between neuropsychiatric symptoms and cognitive decline. All data were collected from patient's medical records at a tertiary referral hospital, so the sample may not represent patients with neurodegenerative disorders in the community. Our study had a small sample size. The authors suggest that future studies use large samples and complementary cognitive assessment tools.
5.2. Conclusions
According to our results, apathy, agitation, delusion, visual hallucination, and sleep disturbances are correlated with cognitive decline in various domains. The present findings indicate the power of behavioral symptoms for predicting cognitive patterns in evaluating neurological disorders. The results suggest using behavioral assessment to predict cognitive disturbance with considerable predictive ability. These symptoms may reflect neuronal loss and degenerative alterations caused by various neuropathological processes.